Evidence map›Paper›PMID 28404862›Full record

ReviewScience translational medicine2017

Engagement of the medical-technology sector with society.

David Williams, Elazer R Edelman, Milica Radisic, Cato Laurencin, Darrel Untereker

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Implementation science: from evidence to practice.Acta medica colombiana : AMC : organo de la Asociacion Columbiana de Medicina Interna
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

David WilliamsProfessor of Biomaterials and Director of International Affairs, Wake Forest Institute of Regenerative Medicine, Winston-Salem, NC 27191, USA. dfwillia@wakehealth.edu eedelman@mit.edu.ORCID 0000-0001-5173-3157
Elazer R EdelmanMIT Cabot Professor of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. dfwillia@wakehealth.edu eedelman@mit.edu.ORCID 0000-0002-7832-7156
Milica RadisicProfessor at Institute of Biomaterials and Biomedical Engineering, Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0003-1249-4135
Cato LaurencinUniversity Professor at University of Connecticut and CEO of Connecticut Institute for Clinical and Translational Science, Farmington, CT 06030, USA.ORCID 0000-0001-6765-3047
Darrel UnterekerVice President of Research and Technology, Medtronic Inc., Minneapolis, MN 55432, USA.

Funding

Vascular Drug Delivery - Supplement for EquipmentR01GM049039 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI EDELMAN, ELAZER R · 1994 to 2019
$8.9M
NIGMS NIH HHS R01 GM049039
6 · The paper itself

Abstract

The medical-technology sector must educate society in an unbiased rational way about the successes and benefits of biotechnology innovation.

Indexed as

BiotechnologyDelivery of Health CareHumansUnited States

Identifiers

PMID28404862
PMCPMC6104832

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.